natgillin/translations-raw huggingface dataset:
Immune response to A/Netherlands/602/9 (H1N1)v-like1
Delež odziva na cepivo2
Immune response to A/Netherlands/602/9 (H1N1)v-like1
Imunski odziv proti A/Netherlands/602/9 (H1N1)v- podobnemu sevu1
Immune response to A/Vietnam/1194/2004
Imunski odziv proti A/Vietnam/1194/2004 (D42)
Immune response to A/Vietnam/1194/2004 (D42)
Imunski odziv proti A/Vietnam/1194/2004 (D42)
Immune response to A/Vietnam/1194/2004 3-5 years
Imunski odziv proti A/Vietnam/1194/2004 3 do 5 let
Immune response to A/Vietnam/1194/2004 6-9 years
Imunski odziv proti A/Vietnam/1194/2004 6 do 9 let
Immune response to Gardasil 9 at month 7
Imunski odziv na cepivo Gardasil 9 v 7. mesecu
Immune response to Pandemrix (H1N1)v
Imunski odziv na cepivo Pandemrix (H1N1)v
Immune responses in preterm and term infants were compared using the proportion of subjects achieving a pneumococcal polysaccharide IgG binding antibody concentration ≥0.35 μg/ml 1 month after the infant series, the approach used for immunogenicity comparisons of Prevenar 13 to Prevenar based on WHO guidelines.
Imunske odzive nedonošenčkov in donošenčkov so primerjali z deležem preskušancev, ki so dosegli koncentracijo protiteles IgG, ki se vežejo na pnevmokokne polisaharide, ki je ≥ 0,35 μg/ml 1 mesec po shemi za dojenčke; to je pristop, ki je bil za primerjavo imunogenosti cepiva Prevenar 13 in cepiva Prevenar uporabljen skladno s priporočili SZO.
Immune responses in toddlers aged 12-14 months
Imunski odzivi pri malčkih, starih od 12 do 14 mesecev
Immune Responses to Gardasil 9 using a 2-dose schedule in individuals 9 through 14 years of age
Imunski odziv na cepivo Gardasil 9 po 2-odmerni shemi cepljenja pri posameznikih, starih od 9 do 14 let
Immune system
Bolezni
Immune system
Bolezni imunskega
immune system (e.g. cyclosporine, tacrolimus, everolimus);
zdravila z delovanjem na imunski sistem (npr. ciklosporin, takrolimus, everolimus);
Immune system disorders
Bolezni imunske ga sistema
Immune system disorders
Bolezni imunskega
Immune system disorders
Bolezni imunskega sisitema
Immune system disorders
Bolezni imunskega sistema sistema
Immune system disorders
Bolezni prebavil
Immune system disorders
Nenavadne
Immune system disorders
Očesne bolezni
Immune System Disorders
sulfonil- sečnino
Immune system disorders
Ónæmiskerfi
Immune system disorders
Žilne bolezni
Immune system disorders Hypersensitivity*
Bolezni imunskega sistema Preobčutljivost
Immune system disorders Nervous system disorders
Bolezni imunskega sistema
Immune system disorders Not known: cases of hypersensitivity reactions such as angioedema, rash, urticaria
Bolezni imunskega sistema Neznana pogostnost: primeri preobčutljivostnih reakcij, kot so angioedem, izpuščaj, urtikarija
Immune system disorders Uncommon Hypersensitivity
Bolezni imunskega sistema občasni preobčutljivost
Immune system disorders*
Bolezni imunskega sistema
Immune System Disorders**
Bolezni imunskega sistema
Immune system disorders6
Bolezni imunskega sistema6
Immune system disorders: anaphylactic reaction, hypersensitivity Nervous system disorders: febrile convulsion
Bolezni imunskega sistema: anafilaktična reakcija, preobčutljivost Bolezni živčevja: febrilne konvulzije
Immune system disorders: anaphylactic reactions
Bolezni imunskega sistema: anafilaktične reakcije
Immune system disorders: Hypersensitivity
Bolezni imunskega sistema: preobčutljivost
Immune system disorders: Hypersensitivity reactions including anaphylactic/anaphylactoid reactions, bronchospasm and urticaria.
Bolezni imunskega sistema: preobčutljivostne reakcije, vključno z anafilaktičnimi/anafilaktoidnimi reakcijami, bronhospazmom in urtikarijo
Immune system disorders: Idiopathic (or thrombotic) thrombocytopenic purpura (increased bruising, bleeding, decreased platelets, anaemia and extreme weakness)
Bolezni imunskega sistema: idiopatična (ali trombotična) trombocitopenična purpura (povečano nastajanje modric, krvavitev, zmanjšano število trombocitov, anemija in ekstremna šibkost).
Immune system disorders: Not known: cases of hypersensitivity reactions such as angioedema, rash, urticaria
Bolezni imunskega sistema: Neznana: primeri preobčutljivostnih reakcij, kot so angioedem, izpuščaj, urtikarija
Immune system disorders: Sarcoidosis (areas of inflamed tissue occurring throughout the body), inflammation of the thyroid
Bolezni imunskega sistema: sarkoidoza (področja vnetega kožnega tkiva po celem telesu), vnetje ščitnice.
Immune system disorders: Severe allergic reaction, systemic lupus erythematosus (an illness where the body attacks its own cells), rheumatoid arthritis (an autoimmune disease)
Bolezni imunskega sistema: huda alergična reakcija, sistemski eritematozni lupus (bolezen, pri kateri telo napade svoje lastne celice), revmatoidni artritis (avtoimunska bolezen).
Immune system disorders: very rare: allergic reactions including anaphylactic and anaphylactoid reactions and serum sickness like disease
Bolezni imunskega sistema: zelo redki: alergijske reakcije, vključno z anafilaksijskimi in anafilaktoidnimi reakcijami in serumski bolezni podobnemu stanju
Immune system disorders: Vogt Koyanagi Harada disease – a rare disease characterised by loss of vision, hearing and skin pigmentation; liver and kidney transplant rejections
Bolezni imunskega sistema: bolezen Vogt Koyanagi Harada – redka bolezen, za katero je značilna izguba vida, sluha in pigmentacije kože; zavrnitev jetrnega in ledvičnega presadka.
Immune system disorders§
Bolezni imunskega sistema§
immune system medicines (e.g. cyclosporine, tacrolimus, everolimus);
zdravila z delovanjem na imunski sistem (npr. ciklosporin, takrolimus, everolimus);
Immune thrombocytopenia
imunska trombocitopenija
Immune Thrombocytopenic Purpura (ITP)
Imunska trombocitopenična purpura (ITP)
immune thrombocytopenic purpura, haemolytic anaemia
imunska trombocitopenična purpura, hemolitična anemija
Immune thrombocytopenic purpura, thrombocytopenia haemoglobin decreased, haematocrit decreased
imunska trombocitopenična purpura, trombocitopenija, znižana raven hemoglobina, znižana vrednost hematokrita
Immune Tolerance Induction (ITI)
Indukcija imunske tolerance (ITI – Immune Tolerance Induction)
immune-mediated adverse events
imunsko pogojenih neželenih učinkih,
Immune-mediated events†
Imunsko pogojeni učinki
Immune-mediated haemolytic anaemia
Imunsko posredovana hemolitična anemija
immune-mediated haemolytic anaemia (antibody-mediated destruction of red blood cells)
imunsko pogojena hemolitična anemija (propad rdečih krvnih celic, ki ga povzročijo protitelesa)
Immune-mediated necrotizing myopathy (see section 4.4).
imunsko posredovana nekrotizirajoča miopatija (glejte poglavje 4.4.)
Immune-related
Imunsko pogojeni
Immune-related colitis symptoms resolve, radiographic abnormalities improve, and management with corticosteroids is complete
Imunsko pogojeni kolitis zadržite dokler simptomi ne izzvenijo, se radiografsko ugotovljene nepravilnosti ne izboljšajo in zdravljenje s kortikosteroidi ni končano.
Immune-related endocrinopathies
imunsko pogojene endokrinopatije
Immune-related gastrointestinal reactions
Imunsko pogojeni neželeni učinki v prebavilih
Immune-related hepatotoxicity
Imunsko pogojeni neželeni učinki na jetra
Immune-related nephritis and renal dysfunction
Imunsko pogojeni nefritis in okvaro delovanja ledvic
Immune-related nephritis or renal dysfunction
Imunsko pogojeni nefritis ali okvara delovanja ledvic
Immune-related nephritis or renal dysfunction
imunsko pogojeni nefritis ali okvaro delovanja ledvic
Immune-related neurological reactions
Imunsko pogojeni neželeni učinki na živčevje
Immune-related rash
Imunsko pogojeni izpuščaj
Immune-related reactions
Imunsko pogojeni neželeni učinki
Immunisation
Cepljenje
Immunisation must be carried out by nasal administration.
Cepljenje je treba opraviti z nazalno uporabo.
Immunisation should be carried out by intramuscular injection into the deltoid muscle or anterolateral thigh (depending on the muscle mass)..
Imunizacijo je treba opraviti z intramuskularnim injiciranjem v deltoidno mišico ali anterolateralni predel stegna (odvisno od mišične mase).
Immunisation should be carried out by intramuscular injection into the deltoid muscle.
Imunizacija se opravi z intramuskularnim injiciranjem v deltoidno mišico.
Immunisation should be carried out by intramuscular injection only, preferably into the deltoid muscle.
Imunizacijo se sme opraviti le z intramuskularnim injiciranjem, po možnosti v deltoidno mišico.
Immunisation should be carried out by subcutaneous injection, preferably into the upper arm (deltoid).
Imunizacija se opravi s subkutanim injiciranjem, najbolje v nadlaket (v deltoidno mišico).
Immunisation with Bexsero is intended to stimulate the production of bactericidal antibodies that recognize the vaccine antigens NHBA, NadA, fHbp, and PorA P1.4 (the immunodominant antigen present in the OMV component) and are expected to be protective against Invasive Meningococcal Disease (IMD).
Imunizacija s cepivom Bexsero je namenjena stimulaciji tvorbe baktericidnih protiteles, ki prepoznavajo cepilne antigene NHBA, NadA, fHbp in PorA P1.4 (imunsko prevladujoči antigen prisoten v OMV komponenti) in za katere se pričakuje zaščitna vloga pred invazivno meningokokno boleznijo.
Immunisation with Improvac resulted in a temporary reduction in the activity of the testicles.
Cepljenje z zdravilom Improvac povzroča začasno zmanjšanje aktivnosti testisov.
Immunisation with live virus vaccines
imunizacija z živimi cepivi;
Immunity is transferred to the chicken’s offspring for a period of 43 weeks after the last vaccination.
Imunost se prenaša na potomce kokoši 43 tednov po zadnjem cepljenju.
Immunity starts after 14 days and lasts for 6 months.
Imunost se začne po 14 dneh in traja šest mesecev.
Immunity test standard
Standard preizkusa odpornosti
Immunization and schedule
Cepljenje in shema
Immunocompromised and pregnant healthcare professionals should not prepare and administer IMLYGIC.
Imunokompromitirani zdravstveni delavci in noseče zdravstvene delavke ne smejo pripravljati in dajati zdravila IMLYGIC.
Immunocompromised individuals (see section 4.3)
Posamezniki z oslabljenim imunskim sistemom (glejte poglavje 4.3)
immunocompromised individuals (see section 4.3),
osebe s pomanjkljivo imunostjo (glejte poglavje 4.3),
Immunocompromised subjects
Imunokomprimirane osebe
Immunocompromised subjects 21 Days After
Bolniki s kroničnimi bolezenskimi stanji
Immunocompromised vaccinees (e.g. dialysis patients, transplant patients, AIDS Patients)
Imunsko kompromitirane cepljene osebe (npr. bolniki na dializi, bolniki po presaditvi, bolniki z AIDS- om)
Immunocompromised/immunosuppressed individuals must not be allowed to handle this vaccine.
Osebam, ki imajo prizadet imunski sistem ne smejo rokovati s tem cepivom.
Immunodeficiency
Imunodeficienca
Immunodeficiency
Imunska pomanjkljivost
ImmunoGam 312 IU/ml solution for injection
ImmunoGam, 312 i.e./ml, raztopina za injiciranje
ImmunoGam 312 IU/ml solution for injection Human Hepatitis B Immunoglobulin
ImmunoGam, 312 i.e./ml, raztopina za injiciranje Človeški imunoglobulin proti hepatitisu B
ImmunoGam contains maltose (10%w/w).
Zdravilo ImmunoGam vsebuje maltozo (10 % m/m).
ImmunoGam has an elimination half-life of 3 – 4 weeks.
Razpolovna doba izločanja zdravila ImmunoGam je 3–4 tedne.
ImmunoGam is supplied in a Type 1 glass vial with a siliconized bromobutyl rubber stopper, aluminum seal and plastic flip-off cap.
Zdravilo ImmunoGam se dobavlja v viali iz stekla tipa I s silikoniziranim zamaškom iz bromobutilnega kavčuka, aluminijastim pečatom in potezno plastično zaporko (»flip-off«).
ImmunoGam provides protection against hepatitis B virus for a short period of time and it is used to treat the following:
Zdravilo ImmunoGam zagotavlja kratkotrajno zaščito pred virusom hepatitisa B in se uporablja za zdravljenje naslednjih stanj:
ImmunoGam should be brought to room temperature (approximately 20 ºC to 25ºC) before use.
Pred uporabo zdravila ImmunoGam počakajte, da se zdravilo segreje na sobno temperaturo (približno od 20 ºC do 25 ºC).
Immunogencity results with two doses of 7.5 µg Focetria H1N1v vaccine from the ongoing clinical trial in adults and elderly are shown below.
Rezultati imunogenosti z dvema odmerkoma 7,5 µg cepiva H1N1v Focetria iz kliničnega preskušanja, ki je v teku pri odraslih in starostnikih, so prikazani spodaj.
Immunogenicity
Ónæmingargeta
Immunogenicity and safety data show that ProQuad can be administered to individuals between 9 and 12 months of age, under special circumstances (e.g., in accordance with official recommendations or when early protection is considered necessary).
Podatki o imunogenosti in varnosti kažejo, da se v posebnih primerih lahko s cepivom ProQuad cepi posameznike, stare od 9 do 12 mesecev (npr. v skladu z uradnimi priporočili ali kadar je nujna zgodnja zaščita).
Immunogenicity and safety in children and adolescents from non-endemic countries
Imunogenost in varnost pri otrocih in mladostnikih iz ne-endemičnih držav
Immunogenicity and safety of IXIARO in children and adolescents from a JEV-endemic country
Imunogenost in varnost cepiva IXIARO pri otrocih in mladostnikih iz držav, kjer je virus japonskega encefalitisa endemičen
Immunogenicity data
Podatki o imunogenosti
Immunogenicity data from three long-term clinical studies indicate that approximately one third of patients develop antibodies, as determined by the mouse neutralisation / mouse protection assay dependent on duration of exposure.
Podatki o imunogenosti iz treh dolgoročnih kliničnih študij kažejo, da se pri približno eni tretjini bolnikov razvijejo protitelesa, kot je bilo ugotovljeno s testom nevtralizacije pri miših/zaščite miši, odvisno od trajanja izpostavljenosti.
Immunogenicity in adolescent (from 11 years of age) and adults
Imunogenost pri mladostnikih (starih več kot 11 let) in odraslih
Immunogenicity in adolescents aged 11-17 years and adults aged ≥ 18 years
Imunogenost pri mladostnikih, starih od 11 do 17 let, in odraslih, starih ≥ 18 let
Immunogenicity in adults
Imunogenost pri odraslih
Immunogenicity in adults aged 18 to 59 years (N=961) and in subjects aged 60 years and older (N=391)
Imunogenost pri odraslih, starih od 18 do 59 let (N=961), in osebah, starih 60 let in več (N=391)
Immunogenicity in children 6 to 11 months, 12 to 23 months and 2 to 10 years of age
Imunogenost pri otrocih, starih od 6 do 11 mesecev, od 12 do 23 mesecev in od 2 do 10 let
Immunogenicity in children aged 2-10 years
Trajanje imunskega odziva pri otrocih, starih od 2 do 10 let
Immunogenicity in elderly persons (≥65 years)
Imunogenost pri starostnikih (starejši od 65 let)
Immunogenicity in HIV infected women
Imunogenost pri ženskah, okuženih s HIV
Immunogenicity in humans
Imunogenost pri ljudeh
Immunogenicity in infants 2 months to 6 months of age
Imunogenost pri dojenčkih, starih od 2 do 6 mesecev
Immunogenicity in infants and children
Imunogenost pri dojenčkih in otrocih
Immunogenicity in males was assessed in 2 clinical trials HPV-011 (N=173) and HPV-040 (N=556).
Imunogenost pri moških so ocenili v dveh kliničnih preskušanjih: HPV-011 (N = 173) in HPV-040 (N = 556).
Immunogenicity in women aged 26 years and older
Imunogenost pri ženskah, starih 26 let in več
Immunogenicity of recombinant human hyaluronidase
Imunogenost rekombinantne humane hialuronidaze
Immunogenicity of Synflorix in very preterm (gestation period of 27-30 weeks) (N=42), preterm (gestation period of 31-36 weeks) (N=82) and full term (gestation period > 36 weeks) (N=132) infants was evaluated following a 3 dose primary vaccination course at 2, 4, 6 months of age.
Imunogenost cepiva Synflorix pri zelo nedonošenih (gestacijska starost od 27 do 30 tednov) (n = 42), nedonošenih (gestacijska starost od 31 do 36 tednov) (n = 82) in donošenih (gestacijska starost > 36 tednov) (n = 132) dojenčkih so ocenili po ciklusu primarnega cepljenja s 3 odmerki pri 2, 4 in 6 mesecih starosti.
Immunogenicity of the vaccine was evaluated in a randomized, active controlled, observer blinded, multicenter Phase 3 clinical trial including 867 healthy male and female subjects given IXIARO or the US licensed JEV vaccine JE VAX (on a 0, 7 and 28 day schedule by subcutaneous injection).
Imunogenost cepiva je bila ovrednotena v randomiziranem, z učinkovino nadzorovanem, slepem, multicentričnem kliničnemu preskušanju 3. faze, v katerega je bilo vključenih 867 zdravih moških in žensk, ki so prejeli cepivo IXIARO ali cepivo proti virusu japonskega encefalitisa, imenovano JE-VAX, ki je bilo odobreno v ZDA (s shemo subkutanega injiciranja na 0., 7. in 28. dan).
Immunogenicity results at one month after Menveo are summarized below in Table 4.
Rezultati imunogenosti en mesec po cepljenju s cepivom Menveo so povzeti spodaj v tabeli 4.
Immunogenicity results from open-labeled studies indicate that PROCOMVAX can be administered concomitantly with DTP (Diphtheria, Tetanus and whole cell Pertussis vaccine), OPV (Oral Poliomyelitis vaccine), IPV ( inactivated poliomyelitis vaccine) and Merck MMR (Measles, Mumps, and Rubella Virus Vaccine Live) using separate sites and syringes for injectable vaccines.
Izsledki o imunogenosti iz odprtih raziskav kažejo, da se PROCOMVAX lahko uporablja sočasno s cepivi DTP (Diphtheria, Tetanus and whole cell Pertussis vaccine - davica, tetanus in polno celično cepivo proti oslovskemu kašlju), OPV (Oral Poliomyelitis vaccine - peroralno cepivo proti poliomielitisu), IPV (inactivated poliomyelitis vaccine - inaktivirano cepivo proti poliomielitisu) in Merckovim cepivom MMR (Measles, Mumps, and Rubella Virus Vaccine Live - cepivo proti ošpicam, mumpsu in živo cepivo proti virusu rdečk), če se cepivo za injiciranje daje na drugo mesto in z drugo brizgo.
Immunogenicity results one month after Menveo vaccination among subjects aged 2-5 years and 6-10 years are summarized below in Table 1
Rezultati imunogenosti en mesec po cepljenju s cepivom Menveo za osebe, stare 2–5 let in 6–10 let so povzete spodaj v tabeli 1.
Immunogenicity results with Focetria H1N1v (Study V111_03):
Rezultati imunogenosti z zdravilom Focetria H1N1v (Študija V111_03):
Immunogenicity sampling information.
Informacije o vzorčenju imunogenih lastnosti.
Immunogenicity to abatacept following long-term subcutaneous administration was assessed by a new ECL assay.
Imunogenost abatacepta po dolgotrajni subkutani uporabi so ovrednotili z novim ECL testom.
Immunogenicity was evaluated by comparing geometric mean titres (GMTs) of strain-specific serum haemagglutination inhibition (HAI) antibodies post dosing.
Imunogenost je bila ocenjena s primerjanjem geometričnega povprečja titrov (GMTs – geometric mean titres) serumskih protiteles specifičnih za sev, ki zavirajo hemaglutinacijo (HAI – haemagglutination inhibition antibodies) po uporabi.
Immunogenicity was measured by (1) the percentage of individuals who were seropositive for antibodies against the relevant vaccine HPV type, and (2) the Geometric Mean Titer (GMT).
Imunogenost so merili z (1) odstotkom oseb, ki so bile seropozitivne glede protiteles proti ustreznemu tipu HPV v cepivu, in (2) geometričnim srednjim titrom (GMT).
Immunogenicity was measured by using rSBA or hSBA which are biomarkers for protective efficacy against meningococcal groups A, C, W-135 and Y.
Imunogenost so določali z uporabo rSBA ali hSBA, ki sta biološka označevalca za zaščitno učinkovitost proti meningokokom skupin A, C, W-135 in Y.
Immunogenicity was related to age and Month 7 anti-HPV levels were significantly higher in younger individuals.
Imunogenost je bila povezana s starostjo, ravni anti-HPV 7. mesec pa so bile pri mlajših osebah značilno večje.
Immunogenicity:
Imunogenost
Immunoglobulin A: Please tell your doctor if your blood does not have immunoglobulin A (IgA).
Imunoglobulin A: obvestite zdravnika, če vaša kri ne vsebuje imunoglobulina A (IgA).
Immunoglobulin administration may impair for a period of at least 6 weeks and up to 3 months the efficacy of live attenuated virus vaccines such as measles, rubella, mumps, and varicella.
Uporaba imunoglobulina lahko za vsaj 6 tednov do 3 mesecev poslabša učinkovitost živih atenuiranih virusnih cepiv, kot so ošpice, rdečke, mumps in norice.
Immunoglobulin is not to be given with PANDEMIC INFLUENZA VACCINE H5N1 BAXTER.
Cepiva PANDEMIC INFLUENZA VACCINE H5N1 BAXTER ne uporabljajte hkrati z imunoglobulini.
Immunoglobulin is not to be given with VEPACEL unless it is necessary during a medical emergency to provide immediate protection.
Skupaj s cepivom VEPACEL se ne daje imunoglobulinov, razen v nujnem primeru za zagotavljanje takojšnje zaščite.
Immunoglobulin: 100 mg/ml, at least 98% is IgG
Imunoglobulin: 100 mg/ml, od tega vsaj 98 % IgG
Immunoglobulins are also known as antibodies and are found in healthy people’s blood.
Imunoglobuline imenujemo tudi protitelesa in so prisotna v krvi zdravih oseb.
Immunoglobulins are excreted into the milk and may contribute to protecting the neonate from pathogens which have a mucosal portal of entry.
Imunoglobulini se izločajo v materino mleko in lahko prispevajo k zaščiti novorojenca pred bolezenskimi povzročitelji, ki vstopajo preko sluznic.
Immunoglobulins are normal constituents of the human body, therefore toxicity testing in heterologous species is of no relevance.
Imunoglobulini so normalna sestavina človeškega telesa, zato testiranje njihove toksičnosti na heterolognih vrstah nima pomena.
Immunoglobulins in general may cause adverse reactions such as chills, headache, fever, vomiting, allergic reactions, nausea, arthralgia (joint pain), low blood pressure and moderate low back pain.
Na splošno se pri uporabi imunoglobulinov lahko pojavijo neželene reakcije, kot so mrazenje, glavobol, zvišana telesna temperatura, bruhanje, alergijske reakcije, slabost, artralgija (bolečine v sklepih), nizek krvni tlak in zmerna bolečina v križu.
Immunologic non-inferiority to 7-valent Prevenar
4.1 Imunološka neinferiornost v primerjavi s 7-valentnim cepivom Prevenar
Immunological properties of the product: To stimulate active immunity in order to provide passive immunity to the progeny against enterotoxicosis caused by E. coli expressing fimbrial adhesins F4ab (K88ab), F4ac (K88ac), F5 (K99), F6 (987P) and against (necrotic) enteritis caused by C. perfringens type C.
Imunološke lastnosti cepiva: Za spodbujanje aktivne imunosti svinj oz. mladic za razvoj pasivne imunosti potomcev proti enterotoksikozi, ki jo povzročijo sevi E. coli, ki izločajo fimbrijske adhezine F4ab (K88ab), F4ac (K88ac), F5 (K99), F6 (987P), in proti (nekrotičnemu) enteritisu , ki ga povzroča tip C C. perfringens.
Immunomedics GmbH Otto-Röhm-Straße 69 D-64293 Darmstadt Germany
Immunomedics GmbH Otto-Röhm-Straße 69 D-64293 Darmstadt Nemčija
Immunomodulation in adults, children and adolescents (2-18 years) in:
Imunomodulacija pri odraslih, otrocih in mladostnikih (2–18 let) pri:
Immunomodulatory medicinal products, including belimumab, may increase the risk of malignancy.
Imunomodulirajoča zdravila, vključno z belimumabom, lahko povečajo tveganje za malignome.
Immunoprophylaxis of Hepatitis B
Imunoprofilaksa proti hepatitisu B:
Immunoprophylaxis of hepatitis B in haemodialysed patients
Imunoprofilaksa proti hepatitisu B pri bolnikih na hemodializi
Immunoprophylaxis of hepatitis B in haemodialysed patients:
Imunoprofilaksa proti hepatitisu B pri bolnikih na hemodializi:
immunosuppressant blood levels, renal
imunosupresiva s telaprevirjem je
Immunosuppressant medicines such as tacrolimus or ciclosporin
zaviralci imunske odzivnosti vključno s takrolimusom ali ciklosporinom,
Immunosuppressant use prior to receiving TYSABRI.
Uporaba imunosupresivov pred začetkom zdravljenja z zdravilom TYSABRI.
IMMUNOSUPPRESSANTS
Aktiven
Immunosuppressants
Avanafil
IMMUNOSUPPRESSANTS
etinilestradiol:
Immunosuppressants
Imunosupresivna zdravila
Immunosuppressants
Interakcija
IMMUNOSUPPRESSANTS
norbuprenorfin:
IMMUNOSUPPRESSANTS
PERORALNI KONTRACEPTIVI
Immunosuppressants
tveganja sistemskih učinkov
IMMUNOSUPPRESSANTS
ZDRAVILA ZA ZAVIRANJE IMUNSKE ODZIVNOSTI
Immunosuppressants
Zdravilo
Immunosuppressants (see section 5.2)
Imunosupresivne učinkovine (glejte poglavje 5.2)
Immunosuppressants (tacrolimus, cyclosporine, sirolimus)
Zdravila za zaviranje imunske odzivnosti (takrolimus, ciklosporin, sirolimus)